FDA Warns Of Potential Safety Issues In Nephron Asthma Drug
By Sindhu Sundar (October 1, 2013, 3:58 PM EDT) -- The U.S. Food and Drug Administration issued a safety warning Monday over the potential health risks of Nephron Pharmaceuticals Corp.'s bronchial asthma drug Asthmanefrin, an over-the-counter inhaled solution that the agency said it has been receiving complaints about in the past year.
The FDA said since Asthmanefrin entered the OTC market in September 2012, the agency has received reports about symptoms of chest pain, nausea, increased blood pressure and heart rate, among other negative side effects from taking the drug, according to its safety announcement Monday.
"In light of FDA's concerns about the use of OTC racepinephrine and similar drugs for...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!